Trial
NCT03698552
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI); ADC Therapeutics S.A.
Condition
Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Intervention
ADCT-602
Why stopped
\<75% participation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-12